The Protocol Review and Monitoring System (PRMS) of the CCC consists of a Clinical Scientific Review Committee [CSRC] and its Executive Committee which act together to review all cancer-related clinical protocols for scientific merit, to assign study priorities, and to monitor the scientific progress of trials. Since the last PRMS approval, the CSRC has been reorganized, protocol review criteria have been formalized, PRMS policies and procedures have been established and AN Executive Committee has been created. The streamlined CRC now consists of 18 members (including 2 ex officio) representing all clinical CCC programs and all specialties in clinical oncology, biostatistics, basic science, and population-based research. During monthly meetings, t he committee performs a scientific review of all cancer-related clinical protocols with approval required prior to review by the Institution Review Boards [IRB] of OSU and Columbus Children's Hospital. Primary and secondary reviewers are required to include at a minimum a clinical oncologist [physician] and a biostatistician. Reviews adhere to a review form to assure that all review criteria are addressed. Based on scientific merit and institutional patient resources, the CSRC establishes protocol priorities for accrual in the event that study eligibility criteria may overlap. Ongoing studies are monitored for scientific progress every six months. Investigators of studies that fail to maintain accrual are warned and given three months to increase accrual The CSRC terminates studies that do not show increased accrual, demonstrate an increased number of adverse events, or fail to meet accepted standards of quality control based on formal audits. The Executive Committee of seven CSRC members meets monthly to assign reviews to submitted studies and to assist the CSRC in determining study priorities and in monitoring scientific progress.
| Zhang, Lingling; Yu, Jianhua; Wei, Wei (2018) Advance in Targeted Immunotherapy for Graft-Versus-Host Disease. Front Immunol 9:1087 |
| Jasinski, Daniel L; Li, Hui; Guo, Peixuan (2018) The Effect of Size and Shape of RNA Nanoparticles on Biodistribution. Mol Ther 26:784-792 |
| Gordillo, Gayle M (2018) Reply: Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation. Plast Reconstr Surg 141:320e |
| Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7 |
| Brasky, Theodore M; Hinton, Alice; Doogan, Nathan J et al. (2018) Characteristics of the Tobacco User Adult Cohort in Urban and Rural Ohio. Tob Regul Sci 4:614-630 |
| Saini, Uksha; Suarez, Adrian A; Naidu, Shan et al. (2018) STAT3/PIAS3 Levels Serve as ""Early Signature"" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. Cancer Res 78:1739-1750 |
| Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397 |
| Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145 |
| Fenn, J Daniel; Monsma, Paula C; Brown, Anthony (2018) Axonal neurofilaments exhibit frequent and complex folding behaviors. Cytoskeleton (Hoboken) 75:258-280 |
| Benej, Martin; Hong, Xiangqian; Vibhute, Sandip et al. (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A 115:10756-10761 |
Showing the most recent 10 out of 2602 publications
